Replies to post #6287 on Insmed Inc (INSM)

[surf1944]

7:32AM Insmed announces two patent allowances in the U.S. and Europe (INSM) 15.14 : Co announces two important patent allowances in the U.S. and Europe that strengthen the Company's global patent portfolio. Insmed is focused on the development and commercialization of ARIKACE for at least two identified orphan patient populations: cystic fibrosis patients with Pseudomonas aeruginosa lung infections and patients with non-tuberculous mycobacteria lung infections.